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Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation Leukemia (2015) 29, 2414-2416; doi:10.1038/leu.2015.298
The TEMPI syndrome is a recently described entity characterized by the pentad of Telangiectasias, Erythrocytosis with elevated erythropoietin, Monoclonal gammopathy, Perinephric fluid collections and Intrapulmonary shunting. 1 The prevalence of the disease is not known and few cases have been reported in the literature so far. [1] [2] [3] [4] [5] The exact pathophysiology is not clear either. Erythrocytosis seems to be the initial manifestation of the disease and the condition has been therefore misdiagnosed as Polycythemia Vera in few patients. Erythrocytosis is associated with extreme elevation of erythropoietin level that seems to be correlating with response to therapy. The clinical course is typically followed by severe hypoxemia, 1, 4 which has been attributed to the combination of intrapulmonary shunting and iatrogenic iron deficiency anemia. Perinephric fluids are thought to be related to malformation of lymphatic vessels. 6 In most of the reported cases, the monoclonal protein is found to be IgG kappa. 1, 4 Treatment with bortezomib-based regimens has been used in few of these patients and variable responses have been reported. 5 Some of these responses were remarkable, suggesting a central role for the monoclonal gammopathy in the pathophysiology of this syndrome. 5 This also points to the hypothesis that TEMPI might represent a paraneoplastic syndrome related to the monoclonal gammopathy, in a similar way to POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-protein and Skin abnormalities), scleromyxoedema or Schnitzler syndrome. [7] [8] [9] In this letter, we report a patient with the TEMPI syndrome that had a dramatic and durable complete clinical and hematological response after high dose chemotherapy and autologous stem cell transplantation (ASCT).
A 49-year-old female was referred to our institution for further evaluation of progressive hypoxia requiring the continuous use of high concentrations of oxygen. She had a 15-year history of erythrocytosis, thought to be related to Polycythemia Vera, and has been treated with intermittent phlebotomy since then. The phlebotomy procedures have resulted in long-standing iatrogenic iron deficiency anemia. Physical examination was significant for remarkable telangiectasia on the face and upper chest and oxygen saturation was 77% on room air. Hemoglobin at presentation was 10.7 g/dl with indices consistent with iron deficiency anemia. However, the erythrocyte count was 7.1 × 10(12)/l (reference: 3.9-5.03) and the erythropoietin level was 8144 mI U/ml (reference: 2.6-18.5). Serum protein electrophoresis demonstrated an IgG kappa monoclonal gammopathy of 1.8 g/dl. Bone marrow biopsy was significant for absent iron stores and the presence of 5-10% monotypic kappa plasma cells. Imaging revealed perinephric fluid collections ( Figure 1) . A positron emission tomography scan was negative for any bony lesion and plasma vascular endothelial growth factor level was normal. Right to left circulatory shunt index (using technetium 99 m macroaggregated albumin scan) was 37.4% (normal o 5%).
Therefore, the clinical and laboratory evaluation suggested a diagnosis of TEMPI syndrome. She was started on a weekly regimen of Cy-Bor-D (cyclophosphamide 300 mg/m 2 , bortezomib 1.3 mg/m 2 and dexamethasone 40 mg). After six cycles, a partial hematological response was achieved with minimal clinical improvement. She continued to require oxygen with a right to left shunt index of 31% (Table 1) .
On the basis of the hypothesis that this syndrome may be directly related to plasma cell dyscrasia and as ASCT has been associated with excellent long-term outcomes in other nonmalignant plasma cell proliferative disorders such as systemic amyloidosis, POEMS syndrome and scleromyxedema, 9-11 we elected to offer ASCT to our patient.
Peripheral blood stem cells were mobilized following treatment with filgrastim and plerixafor. She received melphalan 200 mg/m 2 as a conditioning regimen, followed by infusion of 3.2 × 10(6) CD34 cells/kg. She tolerated the transplant process well without significant complications.
Clinical improvement was noted starting few weeks post transplantation. Evaluation 100 days after ASCT showed a hematologic complete remission with negative serum protein electrophoresis and immunofixation, and normalization of the free light chain. Highly sensitive flow cytometry was negative for any plasma cell clonality. She had dramatic improvement in the TEMPI syndrome with resolution of the visible telangiectasias, disappearance of perinephric fluid collections, and normalization of erythrocyte count. Erythropoietin level following transplant was 95 mIU/ml, shunt index was normal at 4%, and room air oxygen saturation was 98%. She had excellent exercise tolerance. Follow-up at 1 year and 2 years post ASCT continued to show complete hematological and clinical response and she continues to be asymptomatic (Table 1) .
This case demonstrates that TEMPI syndrome is consistent with a paraneoplastic process related to plasma cell dyscrasia. ASCT is a viable option for these patients and results in complete clinical and hematological responses. Similar to the reported experience with ASCT in non-malignant plasma cell dyscrasia, [9] [10] [11] ASCT can result in dramatic and long-term responses associated with disappearance of the monoclonal protein and all the paraneoplastic manifestations of the disease. ASCT should be considered for patients with TEMPI syndrome after an inadequate response to bortezomib-based therapy. These criteria with a minor clarifications have been widely used to measure the effectiveness of myeloma therapy clinical trials. 3 The development of effective monoclonal antibodies for the treatment of MM, such as elotuzumab and daratumumab have brought to our attention an urgent problem in which patients achieving complete response (CR) can be erroneously classified using the IMWG criteria.
As currently written, CR in MM requires negative immunofixation for monoclonal (M) protein in the serum and urine. The intended purpose of this requirement was to demonstrate that the M protein secreted by MM cells is no longer detectable ( Table 1) . We are now aware that new monoclonal antibodies developed for the treatment of MM (e.g., daratumumab and elotuzumab) interfere with the assay by immunofixation since they appear as M proteins on immunofixation. An abnormal immunofixation result due to interference of the assay by a therapeutically administered M protein was not foreseen by us.
The purpose of this letter is to clarify that CR requires disappearance of the original M protein associated with MM on immunofixation, and that the determination of CR is not affected by unrelated M proteins that are secondary to therapeutically administered monoclonal antibodies, biclonal gammopathy, or post-therapy/transplant monoclonal/oligoclonal reconstitution phenomenon. Thus, for example, if a patient with IgA kappa MM treated with a monoclonal antibody has disappearance of the original M protein but has a positive immunofixation for IgG kappa, this finding will not negate the determination of CR. In this case, the IgG kappa M protein will be considered as an artifact from a therapeutically administered antibody (e.g., daratumumab and elotuzumab are both IgG kappa monoclonal antibodies).
Therefore, in order to ensure accuracy, and to reflect the original intended meaning and definition, we have revised the wording of the IMWG definition of CR (Table 1 ). This clarification is critical to enable accurate assessment of CR in trials with monoclonal antibodies in MM. We recognize that the clarification will still result in a modest underestimation of the true CR rate in trials using monoclonal antibodies since it is impossible to distinguish the therapeutic antibody from the patients' M protein if they happen to be of the same heavy-and light-chain isotype. Thus, further updates will be forthcoming once we have validated new assays that can distinguish the two with accuracy. In this regard, we are encouraged by data on a new daratumumab immunofixation reflex assay, in which the binding of an anti-idiotypic antibody to daratumumab altered its electrophoretic migration and thus distinguished the therapeutically administered monoclonal antibody from M protein secreted by MM cells. 4 The role of the Hevylite (San Diego, CA, USA) assay (for lgA and IgG), which has a sensitivity level typically seen with immunofixation, will also need to be studied.
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